期刊
SPHINGOLIPIDS IN CANCER
卷 140, 期 -, 页码 295-325出版社
ELSEVIER ACADEMIC PRESS INC
DOI: 10.1016/bs.acr.2018.04.015
关键词
-
类别
资金
- NCI NIH HHS [P01 CA203628] Funding Source: Medline
Sphingosine kinases (SK1 and SK2) are key, druggable targets within the sphingolipid metabolism pathway that promote tumor growth and pathologic inflammation. A variety of isozyme-selective and dual inhibitors of SK1 and SK2 have been described in the literature, and at least one compound has reached clinical testing in cancer patients. In this chapter, we will review the rationale for targeting SKs and summarize the preclinical and emerging clinical data for ABC294640 as the first-in-class selective inhibitor of SK2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据